81 filings
Page 3 of 5
424B5
u314bdnue2
21 Jul 22
Prospectus supplement for primary offering
4:43pm
8-K
1mvew dzg
21 Jul 22
Other Events
7:01am
424B5
3wnwsm3wdbpgn ndol
20 Jul 22
Prospectus supplement for primary offering
4:22pm
8-K
yi73xn z0iorg
20 Jul 22
Entry into a Material Definitive Agreement
4:08pm
EFFECT
iqnbzswo
13 Jul 22
Notice of effectiveness
12:15am
8-K
iho9p9j8wcmzksin3u9c
12 Jul 22
Other Events
7:00am
8-K
5qk1bqrrbv8y6w7qg
7 Jul 22
Entry into a Material Definitive Agreement
7:06am
S-3
4fwvxm85cq etha
1 Jul 22
Shelf registration
4:36pm
8-K
fnjmari4y7 iuxnl6w
13 Jun 22
Departure of Directors or Certain Officers
4:34pm
8-K
ou7u dsdmwal5
10 May 22
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
6:48am
DEFA14A
k99vkf
29 Apr 22
Additional proxy soliciting materials
7:22am
DEF 14A
r8jk 7he43
29 Apr 22
Definitive proxy
7:01am
S-8
gkyxu0zluuyag1n8odev
14 Mar 22
Registration of securities for employees
7:20am
10-K
az0ja 56t1uk8
14 Mar 22
Annual report
7:04am
8-K
2gswj 9kn
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am
8-K
lcpm0860uo njazbsjt
29 Nov 21
Departure of Directors or Certain Officers
5:09pm
8-K
gvbug
10 Nov 21
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
6:56am
8-K
amb26
24 Aug 21
Entry into a Material Definitive Agreement
4:15pm